Search PubMed⌕ Search

Biomedical subjects

P Borum

Publications and source records attributed to P Borum.

45 records · Page 3Linked to original sources
PubMed1979

Nasal methacholine challenge. A test for the measurement of nasal reactivity.

The aim of this study was to develop a test for the measurement of nasal reactivity. Different concentrations of methacholine were sprayed intranasally, and the nasal secretion and blockage were measured in normal subjects. The simple collection and measurement of secretion was found to be a valuable parameter of mucosal reactivity, while measurement of nasal airway resistance was unreliable, due in part to the presence of secretion in the nasal cavity. The methacholine test had a fairly good reproducibility when the amount of secretion was used as the only parameter. It caused a significantly stronger reaction in women than in men. Patients with perennial rhinitis had a more vigorous response than the controls. It is concluded that the methacholine test may prove useful as a sign of perennial rhinitis and also for the objective evaluation of medication, but further studies are warranted.

Adolescent↗
PubMed1979

Intranasal ipratropium: a new treatment for perennial rhinitis.

Eighty micrograms of the topically active parasympatholytic ipratropium were applied intranasally 4 times a day to 20 adult patients with perennial rhinitis and severe watery rhinorrhoea in a double-blind placebo controlled cross-over trial. There was a significant reduction in nasal hypersecretion during ipratropium treatment. Fourteen patients preferred the ipratropium period, 3 the placebo period and 3 had no preference. There were no adverse systemic or local effects. Ipratropium was effective also in patients resistant to glucocorticoids, sodium cromoglycate and antihistaminics. As the drug works immediately it can also be used before exposure to known provocating factors. It is concluded that continuous use of this new medication is of value in the management of severe rhinorrhoea in patients with perennial rhinitis, and that the occasional use is helpful in subjects with infrequent attacks of nasal hypersecretion.

Administration, Intranasal↗
PubMed1979

Depression of nasal mucociliary transport by an aerosol hair-spray.

The nasal mucociliary transport was measured on 15 healthy test subjects, using the saccharine method, before and after exposure to hair-spray and Freon. The hair-spray reduced the mucociliary transport in the nose for more than 1 h, whereas Freon had no effect. Hair-spray must be considered potentially dangerous, and investigations of the mucociliary transport in persons subject to prolonged exposure to hair-spray (ladies' hairdressers) must be relevant.

Adult↗
PubMed1978

Intranasal ipratropium: inhibition of methacholine induced hypersecretion.

The submucous glands of the nose have an abundant innervation from the parasympathetic nervous system, and rhinorrhea, a symptom of perennial rhinitis, is in all probability caused by an increased activity in these nerves. Pharmacological blockade with atropine-like compounds will therefore be a logical method of treatment. Rhinorrhoea was brought about in the laboratory in 15 healthy experimental subjects by the intranasal application of methacholine. The experimental subjects were pretreated with Ipratropium (Atrovent, Boehringer-Ingelheim) or placebo in a double-blind trial and it was found that Atrovent could effectively inhibit the methacholine induced hypersecretion for up to 6 hours, without local or systemic side-effects. The methacholine induced hypersecretion could also be effectively blocked in 10 patients with perennial rhinitis, and an open clinical study demonstrated that Atrovent had an effect on the spontaneous rhinorrhoea of these patients.

Administration, Intranasal↗
PubMedDate not supplied

Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps.

Nasal polyps are commonly treated surgically. Intranasal administration of topical corticosteroids has gained increased acceptance as a treatment alternative. The aim of our study was to compare the efficacy of treatment of two formulations of budesonide with placebo on nasal polyps. At four Danish clinics 138 patients suffering from moderate or severe nasal polyps were randomized to a twice daily treatment with Rhinocort Aqua 128 micrograms, Rhinocort Turbuhaler 140 micrograms or placebo (Astra Draco, Sweden) for 6 weeks. Polyp size (primary efficacy variable), nasal symptoms, sense of smell, and patients' overall evaluation of treatment of efficacy were assessed by scores. Polyp size was reduced significantly in both budesonide treated groups compared with placebo, but there was no statistical difference between the two actively treated groups. Patients' nasal symptom scores was significantly more reduced in the Aqua compared to the Turbuhaler treated group, and both reduced symptom scores were significantly better compared to placebo. Sense of smell was significantly improved in the actively treated groups compared to placebo. The proportion of patients rating substantial or total control over symptoms after 6 weeks treatment was 60.9% and 48.2% in the Aqua and Turbuhaler-treated groups, respectively, which was significantly better compared with 29.8% in the placebo-treated group. Rhinocort Aqua and Rhinocort Turbuhaler were equally well tolerated.

Administration, Intranasal↗